Skip to content

Price / book at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
6.2×-1.0×
Incyte logo
IncyteINCY
3.3×+0.1×
Merck & Co. logo
Merck & Co.MRK
6.5×+1.8×
Johnson & Johnson logo
Johnson & JohnsonJNJ
7.3×+2.1×
ALN
Alnylam PharmaceuticalsALNY
40.8×-41.2×
Biogen logo
BiogenBIIB
1.4×+0.3×

Other financials

Income statement

See full
Revenue$7.0B+4.4%
Gross profit$5.5B+7.6%
Operating income$2.6B+15.6%
Net income$2.0B+53.7%
EPS (diluted)$1.61+54.8%

Balance sheet

See full
Cash & equivalents$7.6B-3.8%
Total debt$22.2B-11.1%
Total equity$23.5B+22.7%
Total assets$56.3B-0.3%

Cash flow

See full
Operating cash flow$2.5B+44.8%
CapEx$117.0M+12.5%
Free cash flow$2.4B+46.8%

Valuation

See full
Market cap$155.75B+23.8%
Enterprise value$170.3B+19.7%
P/E16.9×-4.2×
P/S5.2×+0.9×

Profitability

See full
Gross margin79.4%+1.1pp
Operating margin34.9%+6.3pp
Net margin31%+10.2pp

Returns & leverage

See full
Return on equity43.2%+10.7pp
Debt / equity0.9×-0.4×
Current ratio+0.6×

Where this comes from

Calculated from Gilead Sciences’s reported figures.

Based on the most recent quarter.

The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gilead Sciences's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Gilead Sciences's price / book?
Gilead Sciences (GILD) reported price / book of 7.4× in Q1 2026.
How has Gilead Sciences's price / book changed year-over-year?
Gilead Sciences's price / book increased by 0.9% year-over-year, from 7.3× to 7.4×.
What is the long-term trend for Gilead Sciences's price / book?
Over 4 years (2021 to 2025), Gilead Sciences's price / book has grown at a 12.3% compound annual growth rate (CAGR), from 17.1× to 27.2×.
What does price / book mean?
How the market price compares to the company's accounting net worth.
How do you interpret price / book?
Below 1.0 can flag a market discount to book value (common for distressed or asset-heavy firms); high values reflect intangible value the balance sheet doesn't capture. Most informative for financials and asset-heavy businesses.
How does price / book compare across companies?
A core valuation gauge for banks and insurers; weak for asset-light firms where book value understates economic value.